Home › Funds › Jackson National › JNL/Mellon Healthcare Sector Fund
Fund family: Jackson National · Filed by JNL SERIES TRUST (CIK 933691) · SEC series S000068125
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,282 with, 35 against, 32 abstentions (not counted as with management). Shareholder proposals: 7 FOR, 28 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Jackson National’s manager page (239,981 ballot items across 107 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Jackson National | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 93.4% | 1,264 | 92.4% | 203,335 |
| Backed environmental and social shareholder proposals at US companies | n/a | 9 | 2.8% | 2,611 |
Each ballot item this fund voted is set against the votes of the other Jackson National funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Jackson National funds on 17 items (1.4% of the 1,252 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Jackson National funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| CENCORA, INC. | 2026-03-05 | Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers. | Against | FOR — 11 of 17 Jackson National funds | Against | Approved, 93.2% support |
| INTUITIVE SURGICAL, INC. | 2026-04-30 | To approve, by advisory vote, the compensation of the Company's Named Executive Officers. | Against | FOR — 8 of 14 Jackson National funds | Against | Approved, 94.0% support |
| RADNET, INC. | 2026-06-02 | An advisory vote to approve the compensation of the Company's Named Executive Officers. | Against | FOR — 4 of 6 Jackson National funds | Against | Approved, 94.0% support |
| RADNET, INC. | 2026-06-02 | DIRECTOR: Laura P. Jacobs | Abstain | FOR — 4 of 6 Jackson National funds | Against | — |
| DOXIMITY, INC | 2025-08-28 | To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025. | Against | FOR — 4 of 6 Jackson National funds | Against | Passed (calculated), 96.4% support |
| NUVALENT, INC. | 2026-06-16 | Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D. | Withhold | FOR — 4 of 6 Jackson National funds | Against | Elected, 81.5% support |
| DANAHER CORPORATION | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. A. Shane Sanders | Against | FOR — 7 of 13 Jackson National funds | Against | — |
| DANAHER CORPORATION | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Raymond C. Stevens, Ph.D | Against | FOR — 7 of 13 Jackson National funds | Against | — |
| DANAHER CORPORATION | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Teri L. List | Against | FOR — 7 of 13 Jackson National funds | Against | — |
| MOLINA HEALTHCARE, INC. | 2026-05-06 | To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. | For | AGAINST — 4 of 7 Jackson National funds | For | Passed (calculated), 52.8% support |
| REPLIGEN CORPORATION | 2026-05-14 | Election of Directors Karen A. Dawes | Against | FOR — 4 of 7 Jackson National funds | Against | — |
| MODERNA, INC. | 2026-05-06 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | For | AGAINST — 3 of 5 Jackson National funds | For | Approved, 65.1% support |
| GUARDANT HEALTH, INC. | 2026-06-17 | Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. | Against | FOR — 3 of 5 Jackson National funds | Against | Not approved, 90.8% support |
| RHYTHM PHARMACEUTICALS, INC. | 2026-06-24 | DIRECTOR: David W.J. McGirr | Abstain | FOR — 2 of 3 Jackson National funds | Against | — |
| IRHYTHM HOLDINGS, INC. | 2026-05-27 | To approve the adoption of our 2026 Equity Incentive Plan. | Against | FOR — 2 of 3 Jackson National funds | Against | Approved, 98.0% support |
| VIKING THERAPEUTICS INC | 2026-05-19 | DIRECTOR: J. Matthew Singleton | For | ABSTAIN — 2 of 3 Jackson National funds | For | — |
| VIKING THERAPEUTICS INC | 2026-05-19 | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. | For | AGAINST — 2 of 3 Jackson National funds | For | Approved, 70.2% support |
Download all 17 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 99.3% of this fund’s 1,349 such votes could be given a sector; the other 9 (0.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 1,185 | 32 | 2.7% |
| Industrials | 102 | 2 | 2.0% |
| Consumer Staples | 20 | 1 | 5.0% |
| Technology | 19 | 0 | 0.0% |
| Consumer Discretionary | 14 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 921 | 0 |
| Say-on-Pay | 143 | 0 |
| Audit-related | 133 | 0 |
| Corporate Governance | 57 | 22 |
| Compensation | 49 | 2 |
| Capital Structure | 30 | 0 |
| Other | 11 | 1 |
| Human Rights or Human Capital/workforce | 6 | 6 |
| Shareholder Rights and Defenses | 6 | 1 |
| Other Social Issues | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $497M | 10 | 2 |
| JOHNSON & JOHNSON | April 23, 2026 | $295M | 15 | 1 |
| ABBVIE INC. | May 8, 2026 | $225M | 8 | 1 |
| UNITEDHEALTH GROUP INCORPORATED | June 1, 2026 | $160M | 12 | 1 |
| MERCK & CO., INC. | May 26, 2026 | $154M | 18 | 3 |
| THERMO FISHER SCIENTIFIC INC. | May 20, 2026 | $111M | 13 | 0 |
| AMGEN INC. | May 19, 2026 | $107M | 15 | 1 |
| GILEAD SCIENCES, INC. | April 30, 2026 | $90M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | JOHNSON & JOHNSON | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | ABBVIE INC. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| June 1, 2026 | UNITEDHEALTH GROUP INCORPORATED | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | PFIZER INC. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
1,360 ballot items at 137 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, JNL/Mellon Healthcare Sector Fund voted at 137 shareholder meetings of 133 companies, on 1,360 ballot items in all. Where management made a recommendation, the fund followed it on 95.0% of the items and voted against it 35 times. Its most frequent area of disagreement was corporate governance (22 of its votes against management). It voted on 35 shareholder proposals. It voted FOR the board's own proposals more often than Jackson National's funds as a whole (93.4% against 92.4%). It voted differently from most Jackson National funds on 17 items. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Jackson National’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.